Affy Posts Slight Rise in Q3 Revenues, Looks to Expand Share in GWAS Market | GenomeWeb

This article was originally published on Oct. 22.

By Justin Petrone

Affymetrix last week posted a slight uptick in third-quarter revenue due in part to increased sales of its gene-expression products. Sales for the three months ended Sept. 30 increased 4 percent to $78.2 million, year over year.

In addition, Affy narrowed its net loss during the quarter to $8.8 million from $31.8 million in the year-ago period.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: Plasmodium knowlesi population structure, 'pre-adaptations' in algal ancestors of land plants, and more.

Replication studies that don't quite reflect the original findings underscore the need to better share data, the Wall Street Journal reports.

About two-thirds of proposals to work with select agents are denied — though most proposals that come in don't meet the definition of a restricted experiment, according to an analysis by the Centers for Disease Control and Prevention.

Researchers examine plant and human DNA found on the Shroud of Turin.